Information Provided By:
Fly News Breaks for March 8, 2019
SNDX
Mar 8, 2019 | 08:53 EDT
BTIG analyst Robert Hazlett lowered his price target on Syndax to $19 after its announced miss in the primary Progression-free survival Phase 2 study for Entinostat immuno-oncology combinations in Triple-negative breast cancer and ovarian cancer. The analyst says the company is now prioritizing its pipeline to focus on Entinostat in breast cancer with upcoming readouts expected in Q2. Hazlett is keeping his Buy rating on Syndax.
News For SNDX From the Last 2 Days
There are no results for your query SNDX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.